Trial Profile
Evaluate the Safety, Reactogenicity & Immunogenicity of 2 Antigen Dose Levels of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02 to Healthy PPD-negative Volunteers Aged 18 to 45 Yrs
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs AS02 (Primary) ; GSK 692342 (Primary) ; Mtb72F (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 10 Feb 2011 New trial record